Skip to main content
Log in

Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers

European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

Warfarin responsiveness is characterized by marked interindividual variability. A major portion of this variability is attributed to CYP2C9 and VKORC1 polymorphisms, but almost 50% is still unaccounted for. This paper reports the first prospective study on the association between factor VII R353Q polymorphism and warfarin responsiveness during induction.

Methods

Genotyping for factor VII R353Q and 323D/I polymorphisms was performed in a cohort consisting of 374 patients (198 CYP2C9*1/*1) treated with warfarin who were prospectively followed from warfarin initiation.

Results

Compared with *1/*1-R/R and *1/*1-R/Q genotype carriers, *1/*1-Q/Q homozygotes achieved higher International Normalized Ratio (INR) values while consuming lower warfarin doses. The greater sensitivity was illustrated by 82.1% higher Warfarin Sensitivity Index During Induction (WSIDI) (0.14±0.11 vs. 0.08±0.50 mg-1 Mann–Whitney, P = 0.043). Multiple regression analysis consisting of both genetic and nongenetic factors explained 26% of WSIDI variability, with R353Q genetic polymorphism having a modest yet significant effect and accounting for 1.7% of the overall variability. Moreover, the incidence of overanticoagulation (i.e., INR > 4) was 6.94-fold higher among *1/*1-Q/Q vs. *1/*1-R/R&R/Q carriers during warfarin induction (Pearson chi-square, P = 0.005). These findings were not accounted for by a chance difference in the distribution of VKORC1 genotypes. Analysis of these parameters among the entire cohort, including CYP2C9*2 and CYP2C9*3 variant allele carriers, did not reach statistical significance. Warfarin responsiveness during induction was unrelated to factor VII 323D/I genetic polymorphism.

Conclusions

The response to warfarin during induction is influenced by factor VII R353Q polymorphism. The prospective use of this polymorphism, along with CYP2C9 and VKORC1, may enhance the accuracy of warfarin loading. However, the impact of R353Q polymorphism on overall warfarin response is subtle, and it is therefore unlikely that its use would be of clinical importance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Lamb E (2007) Top 200 prescription drugs of 2006. Pharm Times May:34–37

    Google Scholar 

  2. Wallvik J, Själander A, Johansson L, Bjuhr O, Jansson JH (2007) Bleeding complications during warfarin treatment in primary healthcare centers compared with anticoagulation clinics. Scand J Prim Health Care 25(2):123–128

    Article  PubMed  Google Scholar 

  3. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696

    Article  PubMed  CAS  Google Scholar 

  4. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 124(11):970–979

    PubMed  CAS  Google Scholar 

  5. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–429

    Article  PubMed  CAS  Google Scholar 

  6. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H et al (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95:205–211

    PubMed  CAS  Google Scholar 

  7. Stafford DW (2005) The vitamin K cycle. J Thromb Haemost 3:1873–1878

    Article  PubMed  CAS  Google Scholar 

  8. Caraco Y, Blotnick S, Muszkat M (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83:460–470

    Article  PubMed  CAS  Google Scholar 

  9. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E et al (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110(5):1511–1515

    Article  PubMed  CAS  Google Scholar 

  10. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2):101–110

    Article  PubMed  CAS  Google Scholar 

  11. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A et al (2001) Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 70:159–164

    Article  PubMed  CAS  Google Scholar 

  12. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72(6):702–710

    Article  PubMed  CAS  Google Scholar 

  13. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and Warfarin dose. N Engl J Med 352:2285–2293

    Article  PubMed  CAS  Google Scholar 

  14. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784–792

    Article  PubMed  CAS  Google Scholar 

  15. The International Warfarin Pharmacogenetics Consortium (2009) Estimation of the Warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753–764

    Article  Google Scholar 

  16. Bertolaa JP, Mazoyerb E, Bergmanna JFO, Drouetb L, Simoneaua G, Mahe I (2003) Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment. Thromb Res 109:287–291

    Article  Google Scholar 

  17. Green FR, Kelleher C, Wilkes H, Temple A, Meade TW, Humphries SE (1991) A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 11:540–546

    Article  PubMed  CAS  Google Scholar 

  18. Van't Hooft FM, Silveira A, Tornvall P, Iliadou A, Ehrenborg E, Eriksson P et al (1999) Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 93:3432–3441

    Google Scholar 

  19. Grimaudo S, Craxi A, Gentile S, Di Paolantonio T, Vaccaro A, Venezia G et al (2005) Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms. Dig Liver Dis 37(6):446–450

    Article  PubMed  CAS  Google Scholar 

  20. Mtiraoui N, Aboud N, Bouraoui H, Haizem S, Gris JC, Busson M et al (2005) Reduction in coagulation factor VII plasma levels by R353Q but not the -323P0/10 promoter polymorphism in healthy Tunisians. Am J Hematol 79:11–16

    Article  PubMed  CAS  Google Scholar 

  21. Jeffery S, Poloniecki J, Leatham E, Bevan D, Ireson N, Talbot S et al (2005) A protective contribution of the Q allele of the R353Q polymorphism of the Factor VII gene in individuals with chronic stable angina? Int J Cardiol 100:395–399

    Article  PubMed  Google Scholar 

  22. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D et al (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79(4):291–302

    Article  PubMed  CAS  Google Scholar 

  23. Lane A, Green F, Humphries S, Ruddock V, Meade T (1995) Effect of factor VII genotype on response to warfarin treatment. Thromb Haemost 73(2):325

    PubMed  CAS  Google Scholar 

  24. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T et al (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630–2635

    Article  PubMed  CAS  Google Scholar 

  25. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23–34

    Article  PubMed  CAS  Google Scholar 

  26. Ken-Dror G, Drenos F, Humphries SE, Talmud PJ, Hingorani AD, Kivimaki et al (2010) Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. J Thromb Haemost 8:2394–2403

    Article  PubMed  CAS  Google Scholar 

  27. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5(3):e1000433, Epub 2009 Mar 20

    Article  PubMed  Google Scholar 

  28. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):160S–198S

    Article  PubMed  CAS  Google Scholar 

  29. Dell'Acqua G, Iacoviello L, D'Orazio A, Di Bitondo R, Di Castelnuovo A, Donati MB (1997) A polymorphic cluster in the 5' region of the human coagulation factor VII gene: detection, frequency, and linkage disequilibrium. Thromb Res 88(5):445–448

    Article  PubMed  Google Scholar 

  30. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254(3):628–631

    Article  PubMed  CAS  Google Scholar 

  31. Gaunt TR, Rodríguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 8:428

    Article  PubMed  Google Scholar 

  32. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of Warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106

    Article  PubMed  CAS  Google Scholar 

  33. Feng D, Tofler GH, Larson MG, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA et al (2000) Factor VII gene polymorphism, Factor VII levels, and prevalent cardiovascular disease: the Framingham heart study. Arterioscler Thromb Vasc Biol 20:593–600

    Article  PubMed  CAS  Google Scholar 

  34. Sakata T, Kario K, Matsuo T, Katayama Y, Matsuyama T, Kato H et al (1995) Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 15(2):241–246

    Article  PubMed  CAS  Google Scholar 

  35. Weinstock DM, Chang P, Aronson DL, Kessler CM (1998) Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. Am J Hematol 57:193–199

    Article  PubMed  CAS  Google Scholar 

  36. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J (2005) Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous Thromboembolism. Br J Haematol 128:513–519

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by a grant from the Bi-National US–Israel Science Foundation (YC), a grant from the Israeli Science Foundation (YC) and a grant from the Israeli Ministry of Health (YC). We greatly appreciate the administrative help of Miss Ilanit Linzer.

Authorship

Contribution: LM declared that she participated in planning the study design, in performing genetic analysis, analyzing data, and writing the paper and that she has seen and approved the final version; IBA declared that she participated in recruiting patients for the study, participated in performing the genetic analysis design, and has seen and approved the final version; MM declared that he participated in recruiting patients for the study and has seen and approved the final version; YC declared that he participated in planning the study design, supervising the study, analyzing data, and writing the paper, and that he has seen and approved the final version.

Conflict of interest

The authors declare no competing financial interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yoseph Caraco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mlynarsky, L., Bejarano-Achache, I., Muszkat, M. et al. Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. Eur J Clin Pharmacol 68, 617–627 (2012). https://doi.org/10.1007/s00228-011-1143-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-011-1143-z

Keywords

Navigation